China-based biopharmaceutical firm BeiGene (BGNE) has received approval for its anti-PD-1 antibody tislelizumab from the China National Medical Products Administration (NMPA) for the …
Biotechnology company Beigene Ltd. (BGNE) has received conditional approval for BRUKINSA from the China National Medical Products Administration (NMPA) for treating Waldenström’s macroglobulinemia …
Commercial-stage biotechnology company BeiGene Ltd. reported data on the combination of tislelizumab and sitravatinib, which is being evaluated for the treatment of solid …
BeiGene (BGNE) and Assembly Biosciences (ASMB) have announced a new collaboration in China for Assembly’s three clinical-stage core inhibitor candidates for the treatment of chronic …
Amgen (AMGN) has announced an additional investment of approximately $421 million in BeiGene’s (BGNE) registered direct offering of ordinary shares. This investment maintains Amgen’s current …
Chinese biotech BeiGene (BGNE) has announced the pricing of a registered direct offering of 145,838,979 ordinary shares, par value $0.0001 per share to …
Hutchison China MediTech (HCM) and BeiGene (BGNE) have now entered into a clinical collaboration agreement for the treatment of various solid tumor cancers. …
These stocks were recommended by Smarter Analyst’s newsletter BioPortfolio, a standout investment resource that allows each subscriber to see the newsletter’s whole history- …